Literature DB >> 22947272

Matrix metalloproteinase-9 (MMP-9) and myeloperoxidase (MPO) levels in patients with nonobstructive coronary artery disease detected by coronary computed tomographic angiography.

Zhi-Hui Hou1, Bin Lu, Yang Gao, Hui-Li Cao, Fang-Fang Yu, Na Jing, Xi Chen, Xiang-Feng Cong, Sion K Roy, Matthew J Budoff.   

Abstract

RATIONALE AND
OBJECTIVES: The aim of this study was to evaluate whether matrix metalloproteinase-9 (MMP-9) and myeloperoxidase (MPO) are elevated in patients with nonobstructive coronary artery disease.
MATERIALS AND METHODS: Eighty-four patients with nonobstructive coronary artery disease (group A) and 90 patients with no coronary plaques (group B) were enrolled. MMP-9 and MPO levels were compared between the two groups. The relationships between these biomarkers and Framingham risk score were analyzed. Receiver-operating characteristic curves were used to evaluate the ability of these biomarkers to predict the presence of coronary artery plaques.
RESULTS: The MMP-9 and MPO values in group A were significantly higher than in group B (P < .001). The levels of MMP-9 and MPO showed significant correlations with Framingham risk score (r = 0.796, P < .001, and r = 0.409, P < .001, respectively). The areas under the receiver-operating characteristic curves for MMP-9 and MPO were 0.80 (95% confidence interval, 0.74-0.87) and 0.74 (95% confidence interval, 0.66-0.81), respectively.
CONCLUSIONS: Levels of MMP-9 and MPO are positively correlated with Framingham risk score. Additionally, in patients with nonobstructive coronary artery disease, elevated levels of MMP-9 and MPO may identify patients at risk for future myocardial infarction or sudden cardiac death.
Copyright © 2013 AUR. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22947272     DOI: 10.1016/j.acra.2012.07.014

Source DB:  PubMed          Journal:  Acad Radiol        ISSN: 1076-6332            Impact factor:   3.173


  4 in total

1.  Osteopontin is proteolytically processed by matrix metalloproteinase 9.

Authors:  Merry L Lindsey; Fouad A Zouein; Yuan Tian; Rugmani Padmanabhan Iyer; Lisandra E de Castro Brás
Journal:  Can J Physiol Pharmacol       Date:  2015-03-26       Impact factor: 2.273

Review 2.  An integrated approach to coronary heart disease diagnosis and clinical management.

Authors:  Teresa Infante; Ernesto Forte; Concetta Schiano; Carlo Cavaliere; Carlo Tedeschi; Andrea Soricelli; Marco Salvatore; Claudio Napoli
Journal:  Am J Transl Res       Date:  2017-07-15       Impact factor: 4.060

3.  Citrate synthase is a novel in vivo matrix metalloproteinase-9 substrate that regulates mitochondrial function in the postmyocardial infarction left ventricle.

Authors:  Lisandra E de Castro Brás; Courtney A Cates; Kristine Y DeLeon-Pennell; Yonggang Ma; Rugmani Padmanabhan Iyer; Ganesh V Halade; Andriy Yabluchanskiy; Gregg B Fields; Susan T Weintraub; Merry L Lindsey
Journal:  Antioxid Redox Signal       Date:  2014-02-19       Impact factor: 8.401

Review 4.  Matrix metalloproteinase-9: Many shades of function in cardiovascular disease.

Authors:  Andriy Yabluchanskiy; Yonggang Ma; Rugmani Padmanabhan Iyer; Michael E Hall; Merry L Lindsey
Journal:  Physiology (Bethesda)       Date:  2013-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.